Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates

TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-W...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 11; no. 11; p. 1682
Main Authors Awasthi, Mayanka, Macaluso, Anthony, Myscofski, Dawn, Prigge, Jon, Koide, Fusataka, Noyce, Ryan S., Fogarty, Siobhan, Stillwell, Helen, Goebel, Scott J., Daugherty, Bruce, Nasar, Farooq, Bavari, Sina, Lederman, Seth
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.11.2023
Subjects
Antibodies
Catheters
COVID-19
Cytokines
Dosage and administration
Effectiveness
Enzymes
horsepox virus
Immunogenetics
Immunogenicity
Immunoglobulin G
Infections
Laboratory animals
Lymphocytes T
Monkeys & apes
Primates
Proteins
Respiratory tract
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Smallpox vaccine
spike protein
Testing
TNX-1800
vaccine
vaccine platform
Vaccines
Viruses
γ-Interferon
United States
United States > US
Online AccessGet full text

Cover

More Information
Summary:TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-WA1/2020 SARS-CoV-2. TNX-1800 vaccination was well tolerated with no serious adverse events or significant changes in clinical parameters. A single dose of TNX-1800 generated humoral responses in African Green Monkeys and Cynomolgus Macaques, as measured by the total binding of anti-SARS-CoV-2 S IgG and neutralizing antibody titers against the USA-WA1/2020 strain. In addition, a single dose of TNX-1800 induced an interferon-gamma (IFN-γ)-mediated T-cell response in Cynomolgus Macaques. Following challenge with SARS-CoV-2, African Green and Cynomolgus Macaques exhibited rapid clearance of virus in the upper and lower respiratory tract. Future studies will assess the efficacy of TNX-1800 against newly emerging variants and demonstrate its safety in humans.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines11111682